Intervention
Senolytics
- Works
- 61
- Clinical trials
- 2
- Total citations
- 18,834
- Open access
- 52
Evidence brief
previewSynthesis (preview — no live AI key for the active provider):
Across the retrieved literature, senescent-cell burden and chronic inflammation recur as central, interacting drivers, with intervention studies reporting functional gains in model organisms. Key works: [1][2][3][4][5].
Publication velocity
20002026
Clinical trials
Huazhong University of Science and Technology 2025
Open access · US-GOV
Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers in Middle-Aged and Older Adults: A Randomized Controlled Trial
Vitality in Aging Research Group, Inc. 2022
Open access · US-GOV
Pilot Study to Test the Safety and Efficacy of Metformin, Dasatinib, Rapamycin and Nutritional Supplements (Bio-quercetin; Bio-fisetin; Glucosamine; Nicotinamide Riboside; Trans-resveratrol) in Reducing Clinical Measures of Aging in Older Adults
Most-cited works
Aging Cell 2015
Open access · CC-BY
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
Nature Medicine 2018
Citation only
Senolytics improve physical function and increase lifespan in old age
Nature Communications 2017
Open access · CC-BY
Cellular senescence mediates fibrotic pulmonary disease
EBioMedicine 2019
Open access · CC-BY
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Genes & Development 2020
Open access · CC-BY
Senescence and the SASP: many therapeutic avenues
Nature 2020
Preprint · OA
Senolytic CAR T cells reverse senescence-associated pathologies
Nature Communications 2017
Open access · CC-BY
Cellular senescence drives age-dependent hepatic steatosis
Nature Medicine 2022
Open access · OA
Cellular senescence and senolytics: the path to the clinic
EBioMedicine 2017
Open access · OA
Cellular Senescence: A Translational Perspective
Nature Communications 2022
Open access · CC-BY